Reference intervals of high-sensitivity troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been determined from Western populations. No data are available regarding expected values in Asian populations.
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Cardiovascular disease, including coronary heart disease, heart failure (HF), 9 and cerebrovascular disease, is the number one cause of death worldwide (1 ) . Whereas cardiovascular diseases were previously maladies of the developed countries, in recent decades, the prevalence of cardiovascular diseases in developing countries has been increasing at an alarming rate. In this regard, the largest increase appears to be coming from the South-East Asia region, where age-adjusted cardiovascular mortality rates increased by 50% in men and 27% in women in a 15-year period despite improvement in access to medical treatments for cardiovascular diseases (2 ) . As life expectancy improves with better nutrition and medical care, the increased duration of exposure to cardiovascular risk factors will lead to an increased global burden of cardiovascular disease, including and especially in Asia.
Understanding how racial, geographical, and demographic differences influence the manifestation of cardiovascular disease is crucially important to better refine methods for diagnosis, estimation of prognosis, and treatment of those so affected (3 ) . In this regard, it should be noted that the majority of scientific evidence for the diagnosis and management of cardiovascular disease has come from Western populations. A portion of this evidence regards the use of biomarkers for patients with suspected acute myocardial infarction (MI) and HF.
For example, acute MI is defined as a combination of an appropriate clinical presentation and a rise and/or fall of serially measured cardiac troponin around the 99th percentile concentration for a healthy population (4 ) . Although troponin is now regarded as the gold standard biomarker in MI diagnosis and is used in several countries, the reference interval data for recently released high-sensitivity troponin T (hscTnT) methods were derived from Western populations (5, 6 ) . No data are currently available regarding the expected concentrations of cardiac troponins in non-Western populations, and there are no data available on the 99th percentile of cardiac troponin in such populations either.
Similarly, B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are both established as biomarkers for HF (7, 8 ) , but the landmark data supporting their use have been based largely on Western populations. To our knowledge, akin to the lack of comparative data for hs-cTnT values, there are no data available comparing concentrations of natriuretic peptides in Western and Eastern populations.
With the rapid rise of cardiovascular disease in Asia, there is an increasing need to establish a better understanding of expected values for gold standard biomarkers of MI and HF in patients from Asian countries. Accordingly, in this study, our objective was to compare values for hs-cTnT and NT-proBNP in selfreported healthy volunteers from the US and Vietnam.
Materials and Methods
Local institutional review boards for each participating institution approved all study procedures, and all patients gave informed consent when appropriate. The approach used in this analysis was consistent with current clinical practice guidelines from the CLSI 2010 update (9 ) .
STUDY DESIGN AND STUDY PARTICIPANT SELECTION
The North South East West (NSEW) Trial was a prospective, age-and sex-matched, cross-sectional, international study of 1157 individuals from 4 hospitals aligned in a north to south fashion in the US (the Massachusetts General Hospital in Boston, MA, and the University of Maryland Medical Center in Baltimore, MD) and Vietnam (Heart Center of the University Medical Center in Ho Chi Minh City and Bach Mai Hospital in Hanoi). Consistent with current clinical practice guidelines (9 ), the age and sex representation selected for the study was fashioned after 2010 US Census data to inform a base case scenario for distribution in this analysis.
Inclusion criteria included individuals 18 years of age and older, and participants had to be self-reported healthy volunteers or blood donors. In the Boston, Ho Chi Minh City, and Hanoi sites, samples were obtained from healthy volunteer blood donors, as identified by blood donor screening questionnaires. In Baltimore, healthy volunteers were recruited and screened with a validated questionnaire, the Roche population selection questionnaire (see Table 1 in the Data Supplement that accompanies the online version of this report at http://www.clinchem.org/content/vol60/issue5), modified to allow for volunteers 18 years or older (6 ) . Baseline demographic data including age, sex, race, weight, height, blood pressure, and pulse were collected at enrollment.
BIOMARKER MEASUREMENT
Following collection of blood from the study participants into tubes containing ethylene diaminotetraacetic acid or no anticoagulant, all blood samples were placed on ice and then subsequently centrifuged. Plasma and serum were transferred to microtubes and frozen at Ϫ80°C.
In a single freeze-thaw cycle, troponin was measured by a 5th generation hs-cTnT assay (TnThs; Roche Diagnostics) that had CVs of 6% and 4% at concentrations of 90.0 and 5530.0 ng/L for the Boston site, 6% and 3.8% at 25.0 and 2200.0 ng/L for the Baltimore site, and 2.3% and 3.6% at 30.5 and 2210.0 ng/L for the Vietnamese sites. This method has a limit of blank of 3.0 ng/L, a limit of detection of 5.0 ng/L, and a widely used 99th percentile value of 14 ng/L.
In a similar fashion, NT-proBNP (Elecsys proBNP®; Roche Diagnostics) had CVs of 5% and 3% at concentrations of 108 and 2990 ng/L for the Boston site, whereas for the Baltimore site CVs were 5.0% at 130 ng/L and 3.0% at 4400 ng/L. Corresponding values were 5% and 3% at 130 and 4400 ng/L, and 1.4% and 0.09% at 133 and 4660 ng/L for the Vietnamese sites. This assay has a limit of detection of 5 ng/L and a measurement range to 35 000 ng/L.
STATISTICS
Differences in categorical variables between 2 groups were assessed using the 2 test. For continuous variables, Student t, Mann-Whitney U, or Kruskal-Wallis tests were employed, as appropriate. Continuous variables were expressed as mean (SD) or median (25th, 75th percentile), the latter reported in the context of data nonnormality.
For assessment of biomarker concentrations in the 2 groups, we followed 3 different approaches. First, we examined unadjusted median concentrations between groups. Next, we evaluated the distribution of biomarker concentrations across both populations; to do so, a sample size of at least 500 in each study group was required to achieve 80% power for detection of a difference between the group proportions of 3% or more with an ␣ of 0.05 by a 2-sided test. Lastly, using Box-Cox-transformed concentrations (to make these biomarker variables as nearly gaussian in distribution as possible), we performed multivariable analysis of covariance on hs-cTnT and NT-proBNP to adjust for baseline characteristics with independent effects [age, sex, race, body-mass index (BMI), systolic and diastolic blood pressure, and pulse]. This was done to mitigate the influence of these variables on results during comparison of the concentrations of each biomarker in the US vs Vietnam.
We considered "measurable" hs-cTnT to be any value above the accepted limit of detection of 5.0 ng/L, but also considered those above the limit of blank (3.0 ng/L) in separate analyses. For comparisons of hscTnT below the limit of detection, a concentration of 2.5 ng/L was imputed, per current convention, whereas concentrations below the limit of blank were imputed to be 1.5 ng/L. In a similar manner, those below the NT-proBNP limit of detection were imputed to have a concentration of 2.5 ng/L. In all statistical analyses, a 2-tailed P value Ͻ0.05 was considered to indicate statistical significance. All analyses were performed with SAS (version 9.2) or PASW (versions 17 and 18) software. Table 1 details baseline characteristics of the study participants. There were no significant differences in age for participants from the US vs Vietnam [41.4 (13.4) vs 41.0 (14.8) years, respectively; P ϭ 0.28]. There were slightly fewer males in the study populations from the US vs Vietnam (44.2% vs 50.7%; P ϭ 0.03) and as expected, 100% of the participants from Vietnam were of Asian ancestry, whereas only 3.2% of participants in the US were. Beyond these basic characteristics, there were several significant differences in baseline characteristics between participants from the US vs Vietnam that could affect both natriuretic peptide and troponin concentrations; participants in the US tended to be heavier, with a BMI of 27.4 (7.3) vs 23.0 (7.5) kg/m 2 , but had slightly lower systolic blood pressure [121 (16) vs 123 (12) mmHg], and lower pulse [71 (11) vs 78 (8) beats per minute], all P Ͻ 0.001. No significant difference in diastolic blood pressure was found. Table 2 details the overall descriptive characteristics of both hs-cTnT and NT-proBNP for the US and Vietnam sites by sex; Fig. 1 and online Supplemental Fig. 1 depict frequency histograms by sex for hs-cTnT and NT-proBNP, respectively, for the US and Vietnamese sites.
Results

BASELINE CHARACTERISTICS
BIOMARKER MEASUREMENTS IN THE US VS VIETNAMESE SITES
With the use of a lower limit of 5.0 ng/L, the unadjusted median (25th, 75th percentile) values for hscTnT were significantly higher in participants from the US than in those from Vietnam value in the US (98.8%) and in Vietnam (98.1%; P ϭ 0.54); correspondingly, 1.2% (n ϭ 7) of the US participants had concentrations above this value compared with 1.7% (n ϭ 10) of the Vietnamese participants. In an exploratory analysis, using values down to the limit of blank, we found that a higher proportion of participants from the US had an hs-cTnT value above 3.0 ng/L (57.2 vs 47.3%; P ϭ 0.05). Other details for 
Fig. 1. Frequency histogram for the distribution of hs-cTnT concentrations by sex for (A) female and (B) male study participants from the US and Vietnam.
The lowest concentration considered in this analysis was the limit of detection (5.0 ng/L, indicated by the asterisk). Values below the limit of detection were imputed as 2.5 ng/L. The accepted 99th percentile value of 14.0 ng/L is indicated by the dotted line.
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data referring to the limit-of-blank analysis are detailed in online Supplemental Table 2 More detailed analyses of hs-cTnT and NTproBNP data across age by decades and sex are shown in Table 3 . Age-and sex-related differences in the concentrations of both biomarkers were seen. Notably, lower NT-proBNP concentrations were seen in the oldest Vietnamese participants; these unexpected data are not explained by lower BMI in this group (data not shown) and may be a play of chance, given the small number of participants in each age category.
In comparative analyses of Box-Cox-transformed values by multivariable regression analysis adjusting for available baseline characteristics that could affect the concentrations of both markers, the difference in hs-cTnT was no longer found to be significant (P Ͼ 0.05), whereas the difference in NT-proBNP remained statistically significant (P ϭ 0.03).
Discussion
Heart disease has achieved epidemic status worldwide, creating increased need to improve the reliability of diagnostic and prognostic evaluation modalities. Given the widespread availability, cost effectiveness, reproducibility, and easy interpretation, biomarker testing has become the standard of care for patients with acute MI and HF, and results from testing both troponins and natriuretic peptides hold prominent places in clinical practice guidelines for these conditions (10, 11 ) . However, detectable concentrations of both of these biomarkers have also been measured in apparently healthy individuals without any cardiovascular diseases. Increased concentrations of these biomarkers have been shown to be quite predictive of future onset of cardiovascular diseases, including HF, and of various adverse outcomes of cardiovascular disease (12, 13 ) , suggesting their potential application to aid in the identification of individuals needing preventive disease interventions in at-risk but well populations.
Although these biomarkers are widely used, there are important caveats about their use. Among the most commonly voiced concerns is the applicability of results from landmark biomarker trials (typically generated in Western populations) in ethnically and geographically distinct groups. A startling lack of data exists in this regard, despite the international use of troponin and natriuretic peptides. Given the rise of cardiovascular disease in Asia, this lack of information has serious ramifications with respect to the use of hscTnT or NT-proBNP. It is in this context that we performed the current study, the largest to date comparing reference concentrations within reference intervals for hs-cTnT and NT-proBNP in self-reported healthy individuals from Western and Asian populations. Applying methods consistent with clinical practice guidelines (9 ), we have found that concentrations of both biomarkers were negligibly higher in study participants from the US compared with those from Vietnam. These differences in concentrations may be partially explained by the higher percentage of women included in the US participants. However, after adjustment for relevant baseline characteristics, the difference in concentrations of hs-cTnT in participants from the US and Vietnam was no longer significant. Notably, the difference in concentrations of NT-proBNP between populations remained statistically significant, with individuals from Vietnam having a lower concentration of NT-proBNP than those from the US. Furthermore, the difference was not clinically significant, because both values were far below the values required for the diagnosis or the determination of prognosis for HF (8, 14 ) or in values for healthy individuals (12 ) . Based on our results, it is logical to regard values for both hs-cTnT and NTproBNP similarly, whether in Western or Asian populations. Further studies with larger numbers of study participants, including a larger population of older patients, are needed to expand on this subject.
There are several potential limitations to our study. One is that our study cohort was relatively small, and was a younger population typical of that seen in the blood bank. Thus, our results may not be generalizable to older patients. However, we enrolled the number of patients needed to have adequate power as determined by our sample size calculation. In context, the CLSI recommendations state that reference limit analyses typically require no more than 120 individuals, far below the sample size in this analysis (9 ) . Thus, a larger study might not have detected significant differences, despite the effects of age on both hs-cTnT and NTproBNP. As stated above, we believe further analyses of this kind, expanded to encompass larger numbers of elderly patients and to consider various interpretation strategies that include adjustment for age and/or sex, would be a noteworthy goal. In addition, our median concentrations of hs-cTnT and NT-proBNP were slightly higher than those commonly accepted. Given our use of individuals who were self-reported to be healthy, we may have included some patients with active cardiovascular and noncardiovascular disorders. Consideration of additional laboratory values and imaging studies for the inclusion of individuals in a study might have been helpful to exclude occult comorbidities, but exceeded the means of this study. Nevertheless, the use of individuals with validated healthy questionnaires and the use of healthy blood donors who have already passed screening for significant active diseases have both been validated to provide good results in screening for healthy reference populations (5 ). Many participants had hs-cTnT between the limit of blank (3.0 ng/L) and limit of detection (5.0 ng/L), and the median values for both groups fell in this range. Despite considerable debate about the validity of such a finding, it is well established that values in this range have prognostic meaning (15, 16 ) . However, when we imputed any value below 5.0 ng/L as half of this value, we found no difference in the results of the study. The use of healthy volunteers to examine reference intervals of either biomarker may have provided reference intervals that cannot be generalized for the interpretation of results in an older, medically complex population, regardless of geography. Although this situation is always a challenge with any reference interval evaluation, in the context of hs-cTnT for the current study, the 99th percentile was based on a healthy population. Lastly, we did not have renal function measures for our study participants; this is a major limitation because chronic kidney disease may substantially impact values for both hs-cTnT and NT-proBNP. That said, use of samples derived from ambulatory well individuals screened for blood donation reduces the likelihood for a substantial number of study participants with impaired renal function.
In conclusion, this is the first adequately powered study comparing the reference intervals of the cardiac biomarkers hs-cTnT and NT-proBNP in Western and Asian populations. We did not find clinically significant differences in the reference ranges of hs-cTnT and NT-proBNP values after adjusting for basic characteristics. This information may have important ramifications in relation to the expanding use of these biomarkers in determining prognosis and management of various cardiac disorders throughout the world. 
